System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Observational Recruiting

NCT04526977 on ClinicalTrials.gov

Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).

Official title: Differences in Susceptibility and Cytokine Profile, Specific CD4/CD8 T Cell Response, Toll Like Receptors (TLRs) and Killer Immunoglobulin-like Receptors (KIRs) Among HIV-1-infected Individuals With Previous or Current COVID-19

  • Sponsor: Asociacion para el Estudio de las Enfermedades Infecciosas
  • Enrollment: 90 (Estimated)
  • Study start: 2021-01-10 (Actual)
  • Primary completion: 2022-12-30 (Estimated)
  • Study completion: 2023-03-30 (Estimated)
  • Allocation: N/a
  • InterventionModel: N/a
  • Masking: None
  • PrimaryPurpose: Other

Brief Summary

People living with HIV could have different susceptibility and outcome to the SARS CoV-2 infection. The risk of SARS CoV-2 infection in this population could be no related to HIV infection, immunodepression or antiretroviral therapy, but to the different susceptibility as measured by ACE2 or CD26 receptors. Also, patients with HIV-1 infection could have different cytokine profile and cellular immune response after SARS-CoV-2 infection, leading to a differential outcome,

Conditions

  • Covid19
  • Immune Suppression
  • HIV-1-infection

Intervention / Treatment

  • Diagnostic Test: Immune response study

Primary Outcome Measures

  • Changes in immune cellular response (3 months)
    Differences in cellular response to SARS-COV-2 peptides

Countries

Spain

Locations and Investigators

  • Hospital Ramon y Cajal, Madrid, Spain (Recruiting)
    • Jose L Casado, Md, PhD
    • Alejandro Vallejo, MD, PhD
    • Pilar Vizcarra, MD
    • Carmen Quereda, MD, PhD
    • Ana Moreno, MD, PhD
    • Jose M Del Rey, MD, PhD

Study Officials